Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Olanzapine“
Suchtreffer
Begriffe & Kennungen
Olanzapine Glenmark Europe · 4.6 Fertility, pregnancy and lactation · 4
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 Undesirable effects · 1
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 Undesirable effects · 2
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 Undesirable effects · 3
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 Undesirable effects · 4
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 10 common adverse reactions associated with the use of olanzapine in this patient group were abnormal gait and
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 11 15 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 22 Tabulated list of adverse reactions The following table lists the adverse reactions and laboratory investig
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 23 anticholinergic distension9 effects including Salivary constipation and hypersecretion11 dry mouth Hepatobi
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 24 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Fol
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 25 In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s d
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 26 Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the m
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 37 Tabulated list of adverse reactions The following table lists the adverse reactions and laboratory investig
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 38 Mild, transient Abdominal distension9 Pancreatitis11 anticholinergic Salivary effects including hypersecret
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 39 body weight was very common (22.2%), ≥ 15% was common (4.2%) and ≥25% was uncommon (0.8%). Patients gaining
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 40 In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s d
Eintrag öffnen